Balanced news tone
News Sentiment
MSCL sentiment intelligence
Satellos Bioscience Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
89/100 classification confidence.
directly relevant articles
high-authority source matches
+24.0% over one week, +68.7% over four weeks, trend inactive, and materially above fair value.
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Satellos Bioscience stock price target raised to $18 by H.C. Wainwright on trial data
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 09 Jul 2026 11:51
- Source
- Investing.com
Satellos (NASDAQ: MSLE) to present new SAT-3247 Duchenne data at ICNMD 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Jun 2026 07:00
- Source
- Stock Titan
Satellos shareholders re-elect board, back PwC at annual meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 07:00
- Source
- Stock Titan
Insider Traders Lose US$134k As Satellos Bioscience Drops
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jun 2026 07:00
- Source
- simplywall.st
We're Not Very Worried About Satellos Bioscience's (TSE:MSCL) Cash Burn Rate
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 18 May 2026 07:00
- Source
- Market source
Satellos price target raised to $40 from $5 at Oppenheimer
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 11 Feb 2026 08:00
- Source
- Market source
Mintz Advises Satellos Bioscience in Its US$57.2 Million Initial US Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Feb 2026 08:00
- Source
- Mintz
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Feb 2026 08:00
- Source
- Business Wire
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Feb 2026 08:00
- Source
- Business Wire
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Feb 2026 08:00
- Source
- Business Wire
Satellos Bioscience is undervalued, Leede says
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jan 2026 08:00
- Source
- Cantech Letter
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jan 2026 08:00
- Source
- Business Wire
Is Satellos Bioscience (TSE:MSCL) In A Good Position To Invest In Growth?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Jan 2026 08:00
- Source
- simplywall.st
Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy (TSX:MSCL:CA)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Sep 2025 07:00
- Source
- Seeking Alpha
Satellos Bioscience Inc (MSCL:CT): Stock Price, Quote and News
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Dec 2024 15:44
- Source
- BNN Bloomberg